Doctors explain how Moderna’s melanoma mRNA vaccine could fight deadliest form of skin cancer

Moderna’s Personalized Melanoma Vaccine Clears Final Pre-Approval Hurdle

Wertynews.com – In what the company called a “landmark moment,” Moderna announced that its experimental mRNA-based shot for melanoma demonstrated the ability to reduce the risk of the aggressive skin cancer recurring or metastasizing. The data emerged from a Phase 3 study — the final clinical stage preceding a potential Food and Drug Administration decision.

The trial enrolled more than 1,100 individuals whose melanoma had already progressed to advanced stages. For each participant, surgeons excised a fragment of the tumor, which was then used as the biological blueprint for a tailored injection.

How the Personalized Shot Targets Melanoma

Once the tumor sample is removed, laboratory analysis identifies the specific genetic mutations unique to that patient’s cancer, according to CBS News chief medical correspondent Dr. Jon LaPook. Artificial intelligence then narrows down which of the hundreds of detected mutations warrant inclusion in the final formulation.

The resulting vaccine functions as a two-part intervention when paired with Merck’s immunotherapy agent Keytruda. Because every dose is constructed from the patient’s own tumor DNA sequence, each shot is individually customized.

“Cancer can put a cloak of invisibility around itself so the immune system can’t see it, and the first punch is a drug called Keytruda, which removes the cloak,” LaPook explained.

Simultaneously, the patient’s cells ingest the synthetic mRNA payload and translate it into a protein, after which the messenger is degraded. That protein effectively educates the immune system to recognize and destroy melanoma cells.

“Think of it like giving a scent to a bloodhound. The vaccine gives the immune system the scent of melanoma so the immune system can hunt it down and kill it,” LaPook said.

Trial Outcomes

For participants whose melanoma had penetrated deeper tissue layers or spread to lymph nodes, Moderna and its development partner Merck reported “statistically significant and clinically meaningful improvement” in the duration patients remained free of detectable cancer.

All trial participants had already undergone surgical tumor removal and received Keytruda as standard immunotherapy. The distinguishing variable was whether the mRNA melanoma vaccine was added. Those who received the additional shot stayed cancer-free for a longer period than those who did not.

Why the Result Matters

Melanoma ranks as the fifth most frequently diagnosed cancer in the United States, accounting for roughly 112,000 new cases annually. The American Cancer Society estimates approximately 8,500 Americans will die from the disease this year.

CBS News medical correspondent Dr. Céline Gounder, who was herself diagnosed with melanoma at a very early stage, characterized the findings as “a big win for mRNA vaccines against cancer.”

The announcement sent Moderna’s shares surging, with the stock more than doubling in value on Wednesday morning.